The effect of OPRM1, ABCB1, IL1B, PTGS2, LOC 541472 gene polymorphism on the variability of chronic pain syndrome in patients with pancreatic cancer

Background. One of the obligate clinical manifestations of pancreatic cancer is chronic pain syndrome, which is realized in 80 % of patients with a progressive course of the disease. Studying the molecular genetic factors that influence the phenotypic realization of chronic pain syndrome in patients with pancreatic cancer is an important step towards personalizing the roadmap.

Aims. To study the associative effect of single nucleotide polymorphisms (SNPs) of the OPRM1, ABCB1, IL1B, PTGS2, LOC 541472 genes on the interindividual variability of chronic pain syndrome in patients with pancreatic cancer.

Materials and methods. The study included 81 patients aged 18 to 75 years with histological verification, promptly treated for prostate cancer according to the main criterion for inclusion in the study. Molecular genetic studies were performed to determine the allelic variants of rs1799971 of the OPRM1 gene, rs1045642, rs2032582, rs1128503 of the ABCB1 gene, rs1143627 of the IL1B gene, rs5275 of the PTGS2 gene, rs1800795 of the LOC gene 541472. Statistical processing of the results was carried out using the Statistica 10.0 program.

Results. Carriers of the homozygous AA genotype of the OPRM1 gene prevailed among the observed patients of the Krasnoyarsk Territory with pancreatic cancer. Genotype AG IL1B showed an increase in the chances of chronic pain by 18,46 times in patients with pancreatic cancer. Carriers of the GG genotypes of the ABCB1 rs1045642 and AA genes of the ABCB1 rs2032582 gene constituted a risk group for the implementation of chronic pain in patients with pancreatic cancer.

Conclusions. The study showed that the most significant in terms of increasing the chances of chronic pain in patients with pancreatic cancer are the homo- and heterozygous genotypes of the IL1B and LOC 541472 genes encoding IL-6.

1. Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;44(22):9694-9705. DOI: 10.3748/wjg.v22.i44.9694

2. Siegel R, Ma J, Zou Z, et al. Cancer statistics 2014. CA Cancer J Clin. 2014;64(1):9-29. DOI: 10.3322/caac.21208

3. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605-1617. DOI: 10.1056/NEJMra0901557

4. Reyes-Gibby CC, Shete S, Yennurajalingam S, et al. Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the infl uence of cytokine genes. J Pain Symptom Manage. 2009;38(6):894-902. DOI: 10.1016/j.jpainsymman.2009.04.019

5. Hamburg MA, Collin FS. The path to personalized medicine. N Engl J Med. 2010;363(4): 301-4. DOI: 10.1056/NEJMp100630

6. Saufferlein T, Bachet JB, van Cutsen E. Rougier P. ESMO Guidelines Working Group. Pancreatic adenocarcinoma: ESMO—ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2012;23:33-40. DOI:10.1093/annonc/mds224

7. Kneuertz PJ, Cunningham SC, Cameron JL, et al. Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience. J Gastrointest. Surg. 2011;15(11):1917-1927. DOI: 10.1007/s11605-011-1665-9

8. Idachaba S, Dada O, Abimbola O, et al. A Review of Pancreatic Cancer: Epidemiology, Genetics, Screening, and Management. Open Access Maced J Med Sci. 2019;28;7(4):663-671. DOI: 10.3889/oamjms.2019.104

9. Koulouris AI, Banim P, Hart AR. Pain in Patients with Pancreatic Cancer: Prevalence, Mechanisms, Management and Future Developments. Dig Dis Sci. 2017;62(4):861-870. DOI: 10.1007/s10620-017-4488-z

10. Uomo I. Pain in Pancreatic Cancer: Does Drug Treatment Still Play a Role? JOP. J Pancreas. 2011;12(5):435-437. PMID:21904067

11. Eds JD, Brierley MK, Gospodarowicz Ch. Wittekind. TNM classification of malignant tumours. 8Thed New York: Wiley-Blackwell; 2017.

12. Hidalgo M. Pancreatic cancer. N Eng J Med. 2010;362: 1605-17. DOI:10.1056/NEJMra0901557

13. Zwisler ST, Enggaard TP, Noehr-Jensen L, et al. The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. Fundam Clin Pharmacol. 2010;24(4):517-524. DOI: 10.1111/j.1472-8206.2009.00781.x

14. Ting, S, Schug S. The pharmacogenomics of pain management: prospects for personalized medicine. J. PainRes. 2016;9:49-56. DOI: 10.2147/JPR.S55595

15. Padoan А, Plebani M, Basso D. Inflammation and Pancreatic Cancer: Focus on Metabolism, Cytokines, and Immunity. Int J Mol Sci https://www.ncbi.nlm.nih.gov/pubmed/30764482. 2019;20(3):1-20. DOI: 10.3390/ijms20030676

16. Bobrova OP, SHnajder NА, Petrova MM, et al. Geneticheskij polimorfizm tsitokinov kak prediktor fenotipicheskoj realizatsii khronicheskogo bolevogo sindroma v onkologii. Sibirskij onkologicheskij zhurnal. 2017;16(5):87-94. (In Russ). https://doi.org/10.21294/1814-4861-2017-16-5-87-94

17. Cann BMc, Miaskowski C, Koetters T, et al. Associations between pro- and anti-inflammatory cytokin. J Pain. 2012;13(5): 425-437. DOI: 10.1016/j.jpain.2011.02.358

18. Yakusheva EN, Chernykh IV, Shhul’kin АV, et al. Glikoprotein-P: struktura, fiziologicheskaya rol’ i molekulyarnye mekhanizmy modulyatsii funktsional’noj aktivnosti. Uspekhi fiziologicheskikh nauk. 2014;45(4):90-98. (In Russ).

19. Fernandez Robles CR, Degnan M, Candiotti KA. Pain and genetics. Curr Opin Anaesthesiol. 2012;25(4):444-449. DOI: 10.1097/ACO.0b013e3283556228